Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-18-386-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Jointly provided by ProCE and the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)

Activity Description

Dramatic shifts have occurred in infectious diseases practice in recent years that can leave clinicians with many questions. Epidemiologic patterns of gram-positive and gram-negative microorganisms have changed considerably, shifting susceptibility patterns and creating distinct challenges in empiric antibiotic prescribing. With these clinical dilemmas looming, it is more important than ever that infectious disease specialists adopt a leadership role in disseminating the latest information on epidemiology and new antimicrobial agents to the wider medical community.

Pharmacists who attend this activity will gain knowledge of current antibiotic resistance trends and infections. Antimicrobial agents will be discussed, with a focus on current limitations and new therapeutic agents on the horizon. Strategies for successful antimicrobial stewardship and outcome measurement plans will also be discussed.

 

Learning Objectives

The target audience for this activity includes infectious disease pharmacists and other health‐system pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this symposium, the participant will be better able to:

• Describe the changing epidemiology and clinical implications of multi-drug resistant infections.
• Review new treatment approaches with current antibiotics, along with their limitations, in the setting of significant antibiotic resistance.
• Compare and contrast new and emerging antimicrobial agents for gram-positive and gram-negative infections, alongside existing antibiotics, to help direct optimal selection of therapy in clinical practice.
• Review antimicrobial stewardship interventions for the use of new antimicrobial agents and strategies to measure the outcomes.

Faculty

Jason C. Gallagher, Pharm.D., FCCP, FIDSA, BCPS
Clinical Professor
Clinical Specialist, Infectious Diseases
Director, PGY2 Residency in Infectious Diseases Pharmacy
Temple University
Philadelphia, Pennsylvania

Jamie Kisgen, PharmD, BCPS-AQ ID
Pharmacy Manager, Infectious Diseases Services
PGY1 Residency Program Director
Sarasota Memorial Health Care System
Sarasota, Florida

CE Accreditation

Pharmacists

Release Date: 2-1-2019
Expiration Date: 2-1-2022

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-051-H01-P has been assigned to this home study knowledge-based activity (initial release date 2-1-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Gallagher has received Research Support from Merck, and is a Speaker and/or Consultant for Accelerate Diagnostics, Achaogen, Allergan, Astellas, Melinta, Merck, Paratek, Shionogi, and Tetraphase. Dr. Kisgen is a Speaker for Merck. A portion of grant funds received by ProCE from Melinta Therapeutics, Inc. will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

    

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.